Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult subjects with moderately to severely active rheumatoid arthritis who start treatment with tofacitinib in usual clinical practice conditions in compliance with the label
1. Patients aged ≥ 18 years
2. Confirmed Diagnosis of Rheumatoid Arthritis by rheumatologist
3. Patients with moderate to severe RA diagnosed according to local practice who have already been started on treatment with tofacitinib, for at most seven working days .
4. Patients eligible for tofacitinib treatment according to current approved Summary of Product Characteristics (SmPC).
5. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
You may not be if
Patients meeting any of the following criteria will not be included in the study:
2. Contraindications to Xeljanz® according to SmPC.
3. Hypersensitivity to the active substance (tofacitinib) or to any of the excipients.
4. Active tuberculosis (TB), serious infections, such as sepsis, or opportunistic infections.
5. Receipt of any investigational drug within 3 months before study inclusion as well as currently not participating in an interventional clinical trial.
6. Subjects who have received any previous treatment with tofacitinib or other JAK inhibitors.
7. Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
